Bis(helenalinyl)malonate is a sesquiterpene lactone dimer isolated from the plant Helenium autumnale, commonly known as sneezeweed. It is a potent anti-inflammatory and cytotoxic agent. The compound has been shown to inhibit the growth of cancer cells in vitro and in vivo. The synthesis of bis(helenalinyl)malonate involves the coupling of two helenalin molecules via a malonate bridge. This compound has also been studied for its potential therapeutic applications in the treatment of inflammatory diseases and cancer. The study of bis(helenalinyl)malonate is driven by its unique chemical structure, potent biological activity, and potential for drug development.'
bis(helenalinyl)malonate: 2 helenalin moieties joined via malonate ester [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 100038 |
| MeSH ID | M0113197 |
| Synonym |
|---|
| 68322-91-8 |
| bis(helenalinyl)malonate |
| propanedioic acid, bis(2,3,3a,4,4a,5,7a,8,9,9a-decahydro-4a,8-dimethyl-3-methylene-2,5-dioxoazuleno(6,5-b)furan-4-yl) ester, (3ar-(3-alpha,4-alpha(3'ar*,4's*,4'ar*,7'ar*,8'r*,9'ar*),4a-beta,7a-alpha,8-alpha,9a-alpha))- |
| brn 5207604 |
| bis(5,8a-dimethyl-1-methylidene-2,8-dioxo-3a,4,5,5a,9,9a-hexahydroazuleno[6,5-b]furan-9-yl) propanedioate |
| nsc 320951 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Bis(helenalinyl)malonate [BHM], a pharmacologically active sesquiterpene lactone potentially useful as an antineoplastic agent, proved to be less toxic than its parent compound, helenalin." | ( Renal, hepatic, cardiac and thymic acute toxicity afforded by bis(helenalinyl)malonate in BDF1 mice. Chaney, SG; Chang, JJ; Grippo, AA; Hall, IH; Holbrook, DJ; Lee, KH; Yang, LM, 1990) | 1.96 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.11) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (14.29%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||